The National Comprehensive Cancer Network released new additions to their guidelines for bladder cancer, including changes to systemic therapy, primary treatments, and adjuvant treatments.
A commonly used gene expression profile test for predicting breast cancer recurrence proves to be less cost-effective in a real-world setting, according to research published in the Journal of Clinical Oncology.
Patients with cancer treated through the Department of Veterans Affairs are less likely to receive excessive end-of-life interventions than patients treated through Medicare.
A recent study compared a targeted therapy with standard chemotherapy for treatment-naïve ALK-positive advanced non-small cell lung cancer.
The new partnership between TransMed and Willowglade will provide help for the Innovative Oncology Business Solutions Triage Pathway to improve clinical decision support technology and alternative payment model reporting.
A recent study summarized the available evidence on adverse events associated with checkpoint inhibitors in patients with cancer and preexisting autoimmune disease.
The FDA has expanded the approval of denosumab for the prevention of skeletal-related events in patients with bone metastasis from multiple myeloma.
The Christiana Care Health System is partnering with Strata Precision Oncology Network to offer next-generation tumor profiling at no cost to patients with advanced or rare cancers.
A recent study identified substantial barriers to standard-of-care therapy for limited-stage small cell lung cancer, including government insurance coverage.
The National Comprehensive Cancer Network recently provided a few major updates to their palliative care guidelines.